Biohaven (BHVN) Common Equity (2021 - 2026)

Biohaven has disclosed Common Equity across 6 years of filings, most recently posting $129.5 million for Q1 2026.

• Common Equity for Q1 2026 came in at $129.5 million, down 50.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $129.5 million (down 50.1% YoY), and the FY2025 annual result was $52.1 million, up 103.87% from the prior year.
• Common Equity came in at $129.5 million for Q1 2026 at Biohaven, up from $52.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $538.8 million in Q4 2022 to a low of -$1.3 billion in Q4 2024.
• The 5-year median for Common Equity is $282000.0 (2023), against an average of -$27.2 million.
• Across the five-year window, Common Equity soared 1453.06% in 2022 and sank 409013.25% in 2024, its largest moves.
• Biohaven's Common Equity stood at $538.8 million in 2022, then dropped by 20.56% to $428.0 million in 2023, then plunged by 414.44% to -$1.3 billion in 2024, then surged by 103.87% to $52.1 million in 2025, then soared by 148.69% to $129.5 million in 2026.
• The last three Common Equity figures came in at $129.5 million (Q1 2026), $52.1 million (Q4 2025), and -$17.2 million (Q3 2025), per Business Quant data.